U.S. may expand Nvidia and AMD’s 15% China chips deal to other companies
Elanco Animal Health (NYSE:ELAN) stock reached a significant milestone, hitting a 52-week high of $15.79. This achievement marks a notable point in the company’s performance for the $7.82 billion market cap company, reflecting investor confidence and market dynamics. According to InvestingPro data, the stock is currently trading above its Fair Value, with analysts setting price targets between $12 and $18. Over the past year, Elanco Animal Health has experienced a 12.68% increase in its stock value, with an impressive 21.09% gain over the past six months, showcasing strong growth and resilience in the competitive animal health industry. The stock’s recent climb to this 52-week high underscores positive sentiment and potential future growth prospects for the company. InvestingPro subscribers have access to 10 additional key insights about Elanco, including detailed analysis of its financial health and growth potential.
In other recent news, Elanco Animal Health has received European Commission approval for its once-daily oral treatment Zenrelia, aimed at managing allergic dermatitis in dogs. This development marks a significant expansion of Elanco’s pet health portfolio in Europe, with plans for product availability before the end of the third quarter of 2025. Additionally, the U.S. Department of Agriculture has approved Elanco’s TruCan Ultra CIV H3N2/H3N8 vaccine for canine influenza, offering protection against two strains of the virus.
In analyst updates, Leerink Partners upgraded Elanco Animal Health to an Outperform rating, citing strong prospects for the company’s Pet Health product launches and growth in the Farm Animal segment. Meanwhile, Stifel raised its price target for Elanco to $17.00, highlighting gains in the parasiticide market, particularly with products like Credelio Quattro, Advantage, and Seresto. These recent developments reflect Elanco’s ongoing efforts to strengthen its position in the animal health industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.